major depressive disorder
Conditions
Interventions
Stable Medication Treatment + tTIS Group:Original therapeutic drug+Transcranial temporal interference stimulation
Stable Medication Treatment + Placebo Capsule Group:Original therapeutic drug+Placebo Capsule
Stable Medication Treatment + Omega-3 PUFAs Group:Original therapeutic drug+Omega-3 PUFAs
Stable Medication Treatment + Sham Stimulation Group:Original therapeutic drug + sham stimulation
Sponsors
Peking University Sixth Hospital ( Institute of Mental Health )
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1.Major Depressive Disorder (MDD) Group: 18-55 years old,Meet the DSM-5 diagnostic criteria for Major Depressive Disorder (MDD); Currently experiencing a depressive episode, defined as a score of >=17 on the 17-item Hamilton Depression Rating Scale (HAMD-17); Anhedonia is assessed using the Dimensional Anhedonia Rating Scale (DARS); Patients with a total DARS score 28 are classified as having the non-anhedonic subtype; Have sufficient visual acuity and comprehension ability to complete all assessments; No electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) treatment in the past 6 months; Able to voluntarily provide written informed consent. 2.Healthy Control Group: Sex- and age-matched healthy controls, matched to the MDD group; HAMD-17 total score <=7; No current or past use of central nervous system (CNS) medications; Voluntarily provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Presence of severe physical or neurological illnesses; 2.Presence of other DSM-5 psychiatric disorders, including personality disorders, neurodevelopmental disorders, substance or alcohol dependence; 3.Severe suicidal ideation or suicidal behaviors; 4.Pregnant or breastfeeding women; 5.Contraindications to magnetic resonance imaging (MRI); 6.Any other conditions judged by the investigators to interfere with study completion or follow-up; 7.Severe impairment in insight or inability/unwillingness to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction rate of HAMD-17 total score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Genetic, epigenetic, and transcriptomic biomarkers;Neuropsychological assessment;Diagnosis;Stress;The severity of anxiety;The severity of anhedonia;The severity of symptoms;Magnetic Resonance Imaging;Immuno-inflammatory, and metabolomic measures; | — |
Countries
China
Contacts
Public ContactSi Tianmei
Peking University Sixth Hospital ( Institute of Mental Health )
Outcome results
None listed